$MD
Pediatrix Medical Group, Inc.

2022 Q1 Form 10-Q Financial Statement

#000095017022006427 Filed on April 28, 2022

View on sec.gov

Income Statement

Concept 2022 Q1 2021 Q1 2020 Q4
Revenue $482.2M $446.8M $416.6M
YoY Change 7.94% 1.26% -9.16%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $404.4M $385.5M $339.4M
YoY Change 4.91% 0.47% -5.54%
% of Gross Profit
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization $8.769M $8.031M $7.700M
YoY Change 9.19% 18.1% -122.92%
% of Gross Profit
Operating Expenses $443.1M $420.6M $371.3M
YoY Change 5.34% 1.53% -4.7%
Operating Profit $39.11M $26.10M
YoY Change 49.82%
Interest Expense $11.82M $17.65M -$21.90M
YoY Change -33.02% -162.57% -16.41%
% of Operating Profit 30.22% 67.6%
Other Income/Expense, Net -$67.45M -$25.72M
YoY Change 162.31%
Pretax Income -$28.35M $389.0K $10.40M
YoY Change -7386.89% -102.24% -25.18%
Income Tax -$7.401M -$4.955M $5.900M
% Of Pretax Income -1273.78% 56.73%
Net Earnings -$21.19M $17.64M -$64.30M
YoY Change -220.1% -194.28% -791.4%
Net Earnings / Revenue -4.39% 3.95% -15.43%
Basic Earnings Per Share -$0.25 $0.21
Diluted Earnings Per Share -$0.25 $0.21 -$767.3K
COMMON SHARES
Basic Shares Outstanding 85.41M 84.53M 85.60M
Diluted Shares Outstanding 85.41M 85.49M

Balance Sheet

Concept 2022 Q1 2021 Q1 2020 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments $96.76M $370.4M $1.229B
YoY Change -73.88% -6.75% 556.01%
Cash & Equivalents $7.179M $269.6M $1.124B
Short-Term Investments $89.58M $100.8M $104.9M
Other Short-Term Assets $9.080M $29.80M $61.81M
YoY Change -69.53% -26.05% 36.44%
Inventory
Prepaid Expenses $16.32M $16.90M
Receivables $317.6M $245.7M $241.9M
Other Receivables $0.00 $19.40M $0.00
Total Short-Term Assets $439.8M $665.4M $1.549B
YoY Change -33.91% -29.28% 111.8%
LONG-TERM ASSETS
Property, Plant & Equipment $72.46M $133.4M $76.19M
YoY Change -45.68% -25.89% -57.03%
Goodwill $1.529B $1.480B
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $128.2M $180.9M $107.4M
YoY Change -29.13% -19.64% -57.47%
Total Long-Term Assets $1.901B $1.818B $1.799B
YoY Change 4.56% -46.19% -47.32%
TOTAL ASSETS
Total Short-Term Assets $439.8M $665.4M $1.549B
Total Long-Term Assets $1.901B $1.818B $1.799B
Total Assets $2.341B $2.484B $3.348B
YoY Change -5.75% -42.5% -19.25%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $30.32M $59.10M $59.77M
YoY Change -48.71% 24.42% 50.94%
Accrued Expenses $222.7M $265.5M $382.3M
YoY Change -16.14% -10.97% -22.86%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $2.404M $2.400M $2.200M
YoY Change 0.17% 242.86% 2100.0%
Total Short-Term Liabilities $269.7M $327.0M $444.3M
YoY Change -17.51% -5.6% -17.99%
LONG-TERM LIABILITIES
Long-Term Debt $804.9M $996.9M $1.743B
YoY Change -19.26% -52.57% 0.71%
Other Long-Term Liabilities $43.87M $331.2M $45.32M
YoY Change -86.75% 2.89% -85.69%
Total Long-Term Liabilities $43.87M $1.328B $45.32M
YoY Change -96.7% -45.21% -97.79%
TOTAL LIABILITIES
Total Short-Term Liabilities $269.7M $327.0M $444.3M
Total Long-Term Liabilities $43.87M $1.328B $45.32M
Total Liabilities $1.464B $1.717B $2.600B
YoY Change -14.74% -39.38% -1.76%
SHAREHOLDERS EQUITY
Retained Earnings -$176.6M -$286.4M
YoY Change
Common Stock $1.055B $1.030B
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $877.1M $766.8M $747.5M
YoY Change
Total Liabilities & Shareholders Equity $2.341B $2.484B $3.348B
YoY Change -5.75% -42.5% -19.25%

Cashflow Statement

Concept 2022 Q1 2021 Q1 2020 Q4
OPERATING ACTIVITIES
Net Income -$21.19M $17.64M -$64.30M
YoY Change -220.1% -194.28% -791.4%
Depreciation, Depletion And Amortization $8.769M $8.031M $7.700M
YoY Change 9.19% 18.1% -122.92%
Cash From Operating Activities -$97.48M -$82.19M -$11.90M
YoY Change 18.61% -42.08% -108.07%
INVESTING ACTIVITIES
Capital Expenditures -$7.145M -$9.100M -$7.000M
YoY Change -21.48% -7.14% -222.81%
Acquisitions $25.67M $5.957M
YoY Change 330.87%
Other Investing Activities -$99.00K $847.6M
YoY Change 460.58%
Cash From Investing Activities -$26.27M -$10.36M $840.6M
YoY Change 153.5% -48.69% 435.41%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net -$8.000K $952.0K
YoY Change -100.84%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -256.5M -761.7M 500.0K
YoY Change -66.33% -308.1% -100.24%
NET CHANGE
Cash From Operating Activities -97.48M -82.19M -11.90M
Cash From Investing Activities -26.27M -10.36M 840.6M
Cash From Financing Activities -256.5M -761.7M 500.0K
Net Change In Cash -380.2M -854.2M 829.2M
YoY Change -55.49% -518.94% 772.84%
FREE CASH FLOW
Cash From Operating Activities -$97.48M -$82.19M -$11.90M
Capital Expenditures -$7.145M -$9.100M -$7.000M
Free Cash Flow -$90.34M -$73.09M -$4.900M
YoY Change 23.6% -44.67% -103.46%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2021Q1 us-gaap Payments Of Financing Costs
PaymentsOfFinancingCosts
CY2021Q1 us-gaap Repayments Of Lines Of Credit
RepaymentsOfLinesOfCredit
CY2022Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2022Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2022Q1 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2022Q1 dei Entity Central Index Key
EntityCentralIndexKey
0000893949
CY2021Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2022Q1 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2021Q1 us-gaap Payments For Proceeds From Other Investing Activities
PaymentsForProceedsFromOtherInvestingActivities
CY2022Q1 us-gaap Income Loss From Discontinued Operations Net Of Tax Per Diluted Share
IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare
CY2021Q1 us-gaap Proceeds From Lines Of Credit
ProceedsFromLinesOfCredit
CY2021Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2021Q1 us-gaap Proceeds From Issuance Of Senior Long Term Debt
ProceedsFromIssuanceOfSeniorLongTermDebt
CY2022Q1 us-gaap Cash Provided By Used In Investing Activities Discontinued Operations
CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations
CY2022Q1 dei Amendment Flag
AmendmentFlag
false
CY2021Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2022Q1 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2022Q1 us-gaap Income Loss From Discontinued Operations Net Of Tax Per Basic Share
IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare
CY2020Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2022Q1 dei Document Type
DocumentType
10-Q
CY2022Q1 dei Document Quarterly Report
DocumentQuarterlyReport
true
CY2022Q1 dei Document Period End Date
DocumentPeriodEndDate
2022-03-31
CY2022Q1 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2022
CY2022Q1 dei Document Transition Report
DocumentTransitionReport
false
CY2022Q1 dei Entity File Number
EntityFileNumber
001-12111
CY2022Q1 dei Entity Registrant Name
EntityRegistrantName
Mednax, Inc.
CY2022Q1 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
FL
CY2022Q1 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
26-3667538
CY2022Q1 dei Entity Address Address Line1
EntityAddressAddressLine1
1301 Concord Terrace
CY2022Q1 dei Entity Address City Or Town
EntityAddressCityOrTown
Sunrise
CY2022Q1 dei Entity Address State Or Province
EntityAddressStateOrProvince
FL
CY2022Q1 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
33323
CY2022Q1 dei City Area Code
CityAreaCode
954
CY2022Q1 dei Local Phone Number
LocalPhoneNumber
384-0175
CY2022Q1 dei Security12b Title
Security12bTitle
Common Stock, par value $.01 per share
CY2022Q1 dei Trading Symbol
TradingSymbol
MD
CY2022Q1 dei Security Exchange Name
SecurityExchangeName
NYSE
CY2022Q1 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2022Q1 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2021Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
21565000
CY2022Q1 md Operating And Finance Lease Right Of Use Assets
OperatingAndFinanceLeaseRightOfUseAssets
66055000
CY2022Q1 dei Entity Filer Category
EntityFilerCategory
Large Accelerated Filer
CY2022Q1 dei Entity Small Business
EntitySmallBusiness
false
CY2022Q1 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2022Q1 dei Entity Shell Company
EntityShellCompany
false
CY2022Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
87261467
CY2022Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
7179000
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
387391000
CY2022Q1 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
89576000
CY2021Q4 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
99715000
CY2022Q1 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
317619000
CY2021Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
301775000
CY2022Q1 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
16323000
CY2021Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
18538000
CY2022Q1 us-gaap Income Taxes Receivable
IncomeTaxesReceivable
0
CY2021Q4 us-gaap Income Taxes Receivable
IncomeTaxesReceivable
14249000
CY2022Q1 us-gaap Other Assets Current
OtherAssetsCurrent
9080000
CY2021Q4 us-gaap Other Assets Current
OtherAssetsCurrent
18896000
CY2022Q1 us-gaap Assets Current
AssetsCurrent
439777000
CY2021Q4 us-gaap Assets Current
AssetsCurrent
840564000
CY2022Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
72458000
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
70154000
CY2022Q1 us-gaap Goodwill
Goodwill
1528694000
CY2021Q4 us-gaap Goodwill
Goodwill
1505430000
CY2022Q1 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
21050000
CY2021Q4 md Operating And Finance Lease Right Of Use Assets
OperatingAndFinanceLeaseRightOfUseAssets
65461000
CY2022Q1 us-gaap Deferred Income Tax Assets Net
DeferredIncomeTaxAssetsNet
84741000
CY2021Q4 us-gaap Deferred Income Tax Assets Net
DeferredIncomeTaxAssetsNet
88344000
CY2022Q1 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
128201000
CY2021Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
131028000
CY2022Q1 us-gaap Assets
Assets
2340976000
CY2021Q4 us-gaap Assets
Assets
2722546000
CY2022Q1 md Accounts Payable And Accrued Liabilities Excluding Accrued Income Taxes Current
AccountsPayableAndAccruedLiabilitiesExcludingAccruedIncomeTaxesCurrent
232089000
CY2021Q4 md Accounts Payable And Accrued Liabilities Excluding Accrued Income Taxes Current
AccountsPayableAndAccruedLiabilitiesExcludingAccruedIncomeTaxesCurrent
394118000
CY2022Q1 us-gaap Finance Lease Liability Current
FinanceLeaseLiabilityCurrent
2404000
CY2021Q4 us-gaap Finance Lease Liability Current
FinanceLeaseLiabilityCurrent
2490000
CY2022Q1 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
20885000
CY2021Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
19684000
CY2022Q1 us-gaap Accrued Income Taxes Current
AccruedIncomeTaxesCurrent
14349000
CY2021Q4 us-gaap Accrued Income Taxes Current
AccruedIncomeTaxesCurrent
11074000
CY2022Q1 us-gaap Liabilities Current
LiabilitiesCurrent
269727000
CY2021Q4 us-gaap Liabilities Current
LiabilitiesCurrent
427366000
CY2022Q1 us-gaap Line Of Credit
LineOfCredit
149000000
CY2021Q4 us-gaap Line Of Credit
LineOfCredit
0
CY2022Q1 md Long Term Debt And Capital Lease Obligations Excluding Long Term Line Of Credit
LongTermDebtAndCapitalLeaseObligationsExcludingLongTermLineOfCredit
655930000
CY2021Q4 md Long Term Debt And Capital Lease Obligations Excluding Long Term Line Of Credit
LongTermDebtAndCapitalLeaseObligationsExcludingLongTermLineOfCredit
1002258000
CY2022Q1 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
40989000
CY2021Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
41396000
CY2022Q1 us-gaap Malpractice Loss Contingency Accrual Undiscounted Noncurrent
MalpracticeLossContingencyAccrualUndiscountedNoncurrent
265082000
CY2021Q4 us-gaap Malpractice Loss Contingency Accrual Undiscounted Noncurrent
MalpracticeLossContingencyAccrualUndiscountedNoncurrent
271093000
CY2022Q1 us-gaap Deferred Income Tax Liabilities Net
DeferredIncomeTaxLiabilitiesNet
39301000
CY2021Q4 us-gaap Deferred Income Tax Liabilities Net
DeferredIncomeTaxLiabilitiesNet
41409000
CY2022Q1 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
43871000
CY2021Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
42332000
CY2022Q1 us-gaap Liabilities
Liabilities
1463900000
CY2021Q4 us-gaap Liabilities
Liabilities
1825854000
CY2022Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
1000000
CY2021Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
1000000
CY2022Q1 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2021Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2022Q1 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2021Q4 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2022Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2022Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
87184000
CY2022Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
87184000
CY2021Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
86423000
CY2021Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
86423000
CY2022Q1 us-gaap Common Stock Value
CommonStockValue
872000
CY2021Q4 us-gaap Common Stock Value
CommonStockValue
864000
CY2022Q1 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
1054141000
CY2021Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
1049696000
CY2022Q1 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-1351000
CY2021Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
1317000
CY2022Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-176586000
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-155390000
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
877076000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
896487000
CY2022Q1 us-gaap Minority Interest
MinorityInterest
0
CY2021Q4 us-gaap Minority Interest
MinorityInterest
205000
CY2022Q1 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
877076000
CY2021Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
896692000
CY2022Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
2340976000
CY2021Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
2722546000
CY2022Q1 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
482229000
CY2021Q1 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
446753000
CY2022Q1 md Practice Salaries And Benefits
PracticeSalariesAndBenefits
343155000
CY2021Q1 md Practice Salaries And Benefits
PracticeSalariesAndBenefits
319012000
CY2022Q1 md Practice Supplies And Other Operating Expenses
PracticeSuppliesAndOtherOperatingExpenses
28489000
CY2021Q1 md Practice Supplies And Other Operating Expenses
PracticeSuppliesAndOtherOperatingExpenses
22212000
CY2022Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
61287000
CY2021Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
66516000
CY2022Q1 us-gaap Restructuring Charges
RestructuringCharges
1421000
CY2021Q1 us-gaap Restructuring Charges
RestructuringCharges
4878000
CY2022Q1 us-gaap Operating Expenses
OperatingExpenses
443121000
CY2022Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
8769000
CY2021Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
8031000
CY2021Q1 us-gaap Operating Expenses
OperatingExpenses
420649000
CY2022Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
39108000
CY2021Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
26104000
CY2022Q1 us-gaap Investment Income Net
InvestmentIncomeNet
875000
CY2021Q1 us-gaap Investment Income Net
InvestmentIncomeNet
5967000
CY2022Q1 us-gaap Interest Expense
InterestExpense
11818000
CY2021Q1 us-gaap Interest Expense
InterestExpense
17645000
CY2022Q1 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-57016000
CY2021Q1 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-14532000
CY2022Q1 us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
505000
CY2021Q1 us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
495000
CY2022Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-67454000
CY2021Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-25715000
CY2022Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-28346000
CY2021Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
389000
CY2022Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-7401000
CY2021Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-4955000
CY2022Q1 us-gaap Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest
IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
-20945000
CY2021Q1 us-gaap Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest
IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
5344000
CY2022Q1 us-gaap Income Loss From Discontinued Operations Net Of Tax
IncomeLossFromDiscontinuedOperationsNetOfTax
-247000
CY2021Q1 us-gaap Income Loss From Discontinued Operations Net Of Tax
IncomeLossFromDiscontinuedOperationsNetOfTax
12290000
CY2022Q1 us-gaap Profit Loss
ProfitLoss
-21192000
CY2021Q1 us-gaap Profit Loss
ProfitLoss
17634000
CY2022Q1 us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
-4000
CY2021Q1 us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
-8000
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-21188000
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
17642000
CY2022Q1 us-gaap Income Loss From Continuing Operations Per Basic Share
IncomeLossFromContinuingOperationsPerBasicShare
-0.25
CY2021Q1 us-gaap Income Loss From Continuing Operations Per Basic Share
IncomeLossFromContinuingOperationsPerBasicShare
0.06
CY2022Q1 us-gaap Income Loss From Continuing Operations Per Diluted Share
IncomeLossFromContinuingOperationsPerDilutedShare
-0.25
CY2021Q1 us-gaap Income Loss From Continuing Operations Per Diluted Share
IncomeLossFromContinuingOperationsPerDilutedShare
0.06
CY2021Q1 us-gaap Income Loss From Discontinued Operations Net Of Tax Per Basic Share
IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare
0.15
CY2021Q1 us-gaap Income Loss From Discontinued Operations Net Of Tax Per Diluted Share
IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare
0.15
CY2022Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.25
CY2021Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.21
CY2022Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.25
CY2021Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.21
CY2022Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
85405000
CY2021Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
84526000
CY2022Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
85405000
CY2021Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
85491000
CY2021Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
896692000
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-21188000
CY2022Q1 md Dissolution Of And Net Income Loss Attributable To Noncontrolling Interest
DissolutionOfAndNetIncomeLossAttributableToNoncontrollingInterest
-203000
CY2022Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-2668000
CY2022Q1 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
1174000
CY2021Q1 us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
-8000
CY2022Q1 us-gaap Stock Repurchased During Period Value
StockRepurchasedDuringPeriodValue
1166000
CY2022Q1 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
877076000
CY2020Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
747717000
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
17642000
CY2021Q1 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
11633000
CY2022Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
16212000
CY2021Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
47799000
CY2022Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
4435000
CY2021Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-1133000
CY2021Q1 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
1042000
CY2021Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
3717000
CY2021Q1 us-gaap Stock Repurchased During Period Value
StockRepurchasedDuringPeriodValue
1994000
CY2021Q1 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
766983000
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-21188000
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
17642000
CY2022Q1 us-gaap Income Loss From Discontinued Operations Net Of Tax
IncomeLossFromDiscontinuedOperationsNetOfTax
-247000
CY2021Q1 us-gaap Income Loss From Discontinued Operations Net Of Tax
IncomeLossFromDiscontinuedOperationsNetOfTax
12290000
CY2022Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
8769000
CY2021Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
8031000
CY2022Q1 us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
577000
CY2021Q1 us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
994000
CY2022Q1 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-57016000
CY2021Q1 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-14532000
CY2022Q1 us-gaap Share Based Compensation
ShareBasedCompensation
4435000
CY2021Q1 us-gaap Share Based Compensation
ShareBasedCompensation
3717000
CY2022Q1 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
2389000
CY2021Q1 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
-16016000
CY2022Q1 us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
605000
CY2021Q1 us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
638000
CY2022Q1 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
20152000
CY2022Q1 us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
-863000
CY2021Q1 us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
90000
CY2022Q1 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-159271000
CY2021Q1 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-106937000
CY2022Q1 us-gaap Increase Decrease In Income Taxes Receivable
IncreaseDecreaseInIncomeTaxesReceivable
17216000
CY2021Q1 us-gaap Increase Decrease In Income Taxes Receivable
IncreaseDecreaseInIncomeTaxesReceivable
-18501000
CY2022Q1 us-gaap Increase Decrease In Liability For Claims And Claims Adjustment Expense Reserve
IncreaseDecreaseInLiabilityForClaimsAndClaimsAdjustmentExpenseReserve
2684000
CY2021Q1 us-gaap Increase Decrease In Liability For Claims And Claims Adjustment Expense Reserve
IncreaseDecreaseInLiabilityForClaimsAndClaimsAdjustmentExpenseReserve
-916000
CY2022Q1 us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
877000
CY2021Q1 us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
-24620000
CY2022Q1 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-89931000
CY2021Q1 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-98926000
CY2022Q1 us-gaap Cash Provided By Used In Operating Activities Discontinued Operations
CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations
-7551000
CY2021Q1 us-gaap Cash Provided By Used In Operating Activities Discontinued Operations
CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations
16738000
CY2022Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-97482000
CY2021Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-82188000
CY2022Q1 us-gaap Payments To Acquire Businesses Net Of Cash Acquired
PaymentsToAcquireBusinessesNetOfCashAcquired
25667000
CY2021Q1 us-gaap Payments To Acquire Businesses Net Of Cash Acquired
PaymentsToAcquireBusinessesNetOfCashAcquired
5957000
CY2022Q1 us-gaap Payments To Acquire Investments
PaymentsToAcquireInvestments
1272000
CY2021Q1 us-gaap Payments To Acquire Investments
PaymentsToAcquireInvestments
5138000
CY2022Q1 us-gaap Proceeds From Sale Maturity And Collections Of Investments
ProceedsFromSaleMaturityAndCollectionsOfInvestments
7712000
CY2021Q1 us-gaap Repayments Of Senior Debt
RepaymentsOfSeniorDebt
759848000
CY2022Q1 us-gaap Proceeds From Issuance Of Senior Long Term Debt
ProceedsFromIssuanceOfSeniorLongTermDebt
650000000
CY2022Q1 us-gaap Payments Of Financing Costs
PaymentsOfFinancingCosts
7924000
CY2022Q1 md Repayments Of Long Term Capital Lease Obligation
RepaymentsOfLongTermCapitalLeaseObligation
747000
CY2021Q1 md Repayments Of Long Term Capital Lease Obligation
RepaymentsOfLongTermCapitalLeaseObligation
672000
CY2022Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
1174000
CY2021Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
1042000
CY2022Q1 us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
1166000
CY2021Q1 us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
1994000
CY2022Q1 us-gaap Proceeds From Payments For Other Financing Activities
ProceedsFromPaymentsForOtherFinancingActivities
86000
CY2021Q1 us-gaap Proceeds From Payments For Other Financing Activities
ProceedsFromPaymentsForOtherFinancingActivities
-189000
CY2022Q1 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
-256457000
CY2021Q1 us-gaap Proceeds From Sale Maturity And Collections Of Investments
ProceedsFromSaleMaturityAndCollectionsOfInvestments
7433000
CY2022Q1 us-gaap Payments To Acquire Other Property Plant And Equipment
PaymentsToAcquireOtherPropertyPlantAndEquipment
7145000
CY2021Q1 us-gaap Payments To Acquire Other Property Plant And Equipment
PaymentsToAcquireOtherPropertyPlantAndEquipment
9052000
CY2022Q1 us-gaap Payments For Proceeds From Other Investing Activities
PaymentsForProceedsFromOtherInvestingActivities
-99000
CY2022Q1 us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-26273000
CY2021Q1 us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-12714000
CY2021Q1 us-gaap Cash Provided By Used In Investing Activities Discontinued Operations
CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations
2350000
CY2022Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-26273000
CY2021Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-10364000
CY2022Q1 us-gaap Proceeds From Lines Of Credit
ProceedsFromLinesOfCredit
248500000
CY2022Q1 us-gaap Repayments Of Lines Of Credit
RepaymentsOfLinesOfCredit
99500000
CY2022Q1 us-gaap Repayments Of Senior Debt
RepaymentsOfSeniorDebt
1046880000
CY2021Q1 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
-761661000
CY2022Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-256457000
CY2021Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-761661000
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-380212000
CY2021Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-854213000
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
387391000
CY2020Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
1123843000
CY2022Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
7179000
CY2021Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
269630000
CY2021Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
301775000
CY2021Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
99715000
CY2022Q1 md Increase Decrease In Accrued Salaries And Bonuses
IncreaseDecreaseInAccruedSalariesAndBonuses
138600000
CY2022Q1 us-gaap Accounts Receivable Gross Current
AccountsReceivableGrossCurrent
1476705000
CY2022Q1 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
1159086000
CY2021Q4 us-gaap Malpractice Loss Contingency Accrual Undiscounted Current
MalpracticeLossContingencyAccrualUndiscountedCurrent
37729000
CY2022Q1 us-gaap Interest Payable Current
InterestPayableCurrent
3205000
CY2021Q4 us-gaap Interest Payable Current
InterestPayableCurrent
29052000
CY2022Q1 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
59480000
CY2021Q4 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
1091809000
CY2022Q1 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
317619000
CY2021Q4 us-gaap Accounts Receivable Gross Current
AccountsReceivableGrossCurrent
1393584000
CY2022Q1 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
482229000
CY2021Q1 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
446753000
CY2022Q1 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
89576000
CY2022Q1 us-gaap Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Intangibles
BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles
1000000.0
CY2021Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
41724000
CY2022Q1 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
232089000
CY2021Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
394118000
CY2022Q1 md Percentage Of Net Patient Service Revenue By Type Of Payor
PercentageOfNetPatientServiceRevenueByTypeOfPayor
1
CY2021Q1 md Percentage Of Net Patient Service Revenue By Type Of Payor
PercentageOfNetPatientServiceRevenueByTypeOfPayor
1
CY2022Q1 us-gaap Business Acquisition Purchase Price Allocation Goodwill Expected Tax Deductible Amount
BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount
23300000
CY2022Q1 us-gaap Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Property Plant And Equipment
BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment
1700000
CY2022Q1 us-gaap Accounts Payable Current
AccountsPayableCurrent
30315000
CY2021Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
36645000
CY2022Q1 us-gaap Accrued Salaries Current
AccruedSalariesCurrent
75419000
CY2021Q4 us-gaap Accrued Salaries Current
AccruedSalariesCurrent
213974000
CY2022Q1 md Accrued Payroll Taxes And Benefits Current
AccruedPayrollTaxesAndBenefitsCurrent
29628000
CY2021Q4 md Accrued Payroll Taxes And Benefits Current
AccruedPayrollTaxesAndBenefitsCurrent
34994000
CY2022Q1 us-gaap Malpractice Loss Contingency Accrual Undiscounted Current
MalpracticeLossContingencyAccrualUndiscountedCurrent
34042000
CY2021 md Increase Decrease In Accrued Salaries And Bonuses
IncreaseDecreaseInAccruedSalariesAndBonuses
138600000
CY2022Q1 us-gaap Debt Instrument Interest Rate Stated Percentage
DebtInstrumentInterestRateStatedPercentage
0.05375
CY2022Q1 us-gaap Debt Instrument Frequency Of Periodic Payment
DebtInstrumentFrequencyOfPeriodicPayment
payable semi-annually in arrears on February 15 and August 15, beginning on August 15, 2022
CY2022Q1 md Purchase Price
PurchasePrice
1.01
CY2022Q1 us-gaap Stock Issued During Period Shares Employee Stock Purchase Plans
StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
0
CY2022Q1 us-gaap Debt Instrument Description
DebtInstrumentDescription
Notes are guaranteed on an unsecured senior basis by the same subsidiaries and affiliated professional contractors that guarantee the Amended Credit Agreement (as defined below). The indenture under which the 2030 Notes are issued, among other things, limits the Company's ability to (1) incur liens and (2) enter into sale and lease-back transactions, and also limits the Company's ability to merge or dispose of all or substantially all of its assets, in all cases, subject to a number of customary exceptions
CY2022Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
4400000
CY2021Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
3700000
CY2022Q1 us-gaap Shares Paid For Tax Withholding For Share Based Compensation
SharesPaidForTaxWithholdingForShareBasedCompensation
50000000
CY2022Q1 us-gaap Debt Instrument Maturity Date
DebtInstrumentMaturityDate
2027-02-11
CY2022Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
85405000
CY2021Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
84526000
CY2022Q1 us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
0
CY2021Q1 us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
965000
CY2022Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
85405000
CY2021Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
85491000
CY2022Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
248000
CY2021Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
18000
CY2022Q1 us-gaap Stock Repurchased During Period Shares
StockRepurchasedDuringPeriodShares
0
CY2018Q3 us-gaap Stock Repurchase Program Authorized Amount1
StockRepurchaseProgramAuthorizedAmount1
500000000.0
CY2021Q4 us-gaap Stock Repurchase Program Remaining Authorized Repurchase Amount1
StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1
94000000.0

Files In Submission

Name View Source Status
0000950170-22-006427-index-headers.html Edgar Link pending
0000950170-22-006427-index.html Edgar Link pending
0000950170-22-006427.txt Edgar Link pending
0000950170-22-006427-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
md-20220331.htm Edgar Link pending
md-20220331.xsd Edgar Link pending
md-20220331_cal.xml Edgar Link unprocessable
md-20220331_def.xml Edgar Link unprocessable
md-20220331_htm.xml Edgar Link completed
md-20220331_lab.xml Edgar Link unprocessable
md-20220331_pre.xml Edgar Link unprocessable
md-ex31_1.htm Edgar Link pending
md-ex31_2.htm Edgar Link pending
md-ex32_1.htm Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending